Polynovo Limited ( (AU:PNV) ) just unveiled an announcement.
PolyNovo Limited has announced a change in leadership with the departure of CEO Mr. Swami Raote, effective June 10, 2025. Dr. Robyn Elliott, a non-executive director with extensive experience in business development and operational strategy, will serve as Acting CEO until a permanent replacement is found. This leadership change is aimed at continuing the company’s growth and transformation, with an executive search for a new CEO underway. The Board is also reviewing its structure and composition to ensure effective governance and succession planning.
More about Polynovo Limited
PolyNovo Limited is a disruptive ASX 200 medical technology company based in Melbourne, Australia. It specializes in products that simplify the management of acute complex wounds, offering differentiated patient outcomes across various wound etiologies. The company has treated over 50,000 patients in 41 countries and is focused on growth through new products, indications, and market expansion.
YTD Price Performance: -22.69%
Average Trading Volume: 5,171
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $521.1M
For an in-depth examination of PNV stock, go to TipRanks’ Stock Analysis page.